|
![]() |
Cancer > Antibodies
The following information is about Antibodies.
Antibodies Defined
A large number of proteins that are produced normally after stimulation by an antigen and act specifically against the antigen in an immune response.
This definition is in context to Cancer. See more contextual defintions for Antibodies.
New blood scanner detects even faint indicators of cancer
Published December 2, 2008, 11:14 am, PhysOrg
A team led by Stanford researchers has developed a prototype blood scanner that can find cancer markers in the bloodstream in early stages of the disease, potentially allowing for earlier treatment and dramatically improved chances of survival.
Cynvec LLCSM to Present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008
Published December 2, 2008, 10:17 am, Centre Daily Times
Cynvec LLC, a privately-held biopharmaceutical company focused on developing novel cancer therapies that harness the apoptotic ability of the Sindbis viral vector, today announced that executive management will participate in the NYSSA 12th Annual Biotech and Specialty Pharma Conference in New York on December 2, 2008. The conference is being held at 1177 Avenue of the Americas, 2nd floor, New ...
Cynvec LLCSM to Present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference on December 2, 2008
Published December 2, 2008, 9:58 am, Business Wire via Yahoo! Finance
NEW YORK----Cynvec LLC, a privately-held biopharmaceutical company focused on developing novel cancer therapies that harness the apoptotic ability of the Sindbis viral vector, today announced that executive management will participate in the NYSSA 12th Annual Biotech and Specialty Pharma Conference in New York on December 2, 2008.
Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study In Platinum-Resistant Ovarian Cancer
Published December 2, 2008, 6:35 am, Centre Daily Times
Morphotek ® , Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of farletuzumab (also known as MORAb-003). The study will evaluate farletuzumab, plus the chemotherapy drug paclitaxel, in patients with platinum-resistant (PR) ovarian cancer. The randomized, controlled trial will compare farletuzumab plus paclitaxel with ...
Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study In Platinum-Resistant Ovarian Cancer
Published December 2, 2008, 6:00 am, Business Wire via Yahoo! Finance
EXTON, Pa.----Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of farletuzumab . The study will evaluate farletuzumab, plus the chemotherapy drug paclitaxel, in patients with platinum-resistant ovarian cancer.
Immunomedics to Present At 50th ASH Annual Meeting
Published December 2, 2008, 5:30 am, GlobeNewswire via Yahoo! Finance
MORRIS PLAINS, N.J., Dec. 2, 2008 -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that seven presentations involving its potential products will be given at the 50th American Society of Hematology Annual Meeting, scheduled for December 6 - 9, 2008, in San Francisco, California.
First Ever In-vivo Efficacy Data For A MicroRNA Therapeutic Disease Model
Published December 1, 2008, 12:10 pm, Medical News Today
Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in the journal Nature on the role of a microRNA, known as miR-21, in heart failure(1).
Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers
Published December 1, 2008, 5:02 am, Centre Daily Times
Symphogen A/S today announced that John Haurum, Chief Scientific Officer and Michael Kragh, Director of Antibody Pharmacology will present positive preclinical data on the Company’s Sym004 program for the discovery and development of antibodies against EGF receptor (EGFR)-positive cancers. The data will be presented at two upcoming conferences: the 4 th Annual European Antibody Congress in ...
Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers
Published December 1, 2008, 4:51 am, Business Wire via Yahoo! Finance
COPENHAGEN, Denmark----Symphogen A/S today announced that John Haurum, Chief Scientific Officer and Michael Kragh, Director of Antibody Pharmacology will present positive preclinical data on the Company’s Sym004 program for the discovery and development of antibodies against EGF receptor -positive cancers.
Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a ...
Published November 30, 2008, 10:21 am, Finanzen.net
Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and ...
Are you looking for additional Cancer > Antibodies news? Try our new "Antibodies News Focus" area.
Off-site Antibodies Links, User Submitted
The following links have been collected through user bookmark submission in the Antibodies category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
Tue Dec 2
- Abcam: Abcam is on a mission "...to build the largest online catalog of the best antibodies in the world" Our scientists are dedicated to building a catalog of the best antibodies in the world. We make our own antibodies and source other excellent antibodies from institutes, academic laboratories and primary manufacturers. We provide technical support on all of our products to enable you to achieve the result you should expect.y
- Products T-Z
Wed Nov 26
Mon Nov 24
- Polyclonal antibodies - Wikipedia, the free encyclopedia
- Antibody Resource Page: Find Monoclonal and Polyclonal Antibodies
- Monoclonal Antibodies: Good article on production and use of monoclonal antibodies
- Affinity Chromatography
Fri Nov 21
- Hope for Rabies Victims: Unorthodox Coma Therapy Shows Promise: Four years ago, Jeanna Giese, now 19, became the first person to survive rabies without a preventive vaccine. Now, the medical procedure developed for treating Giese may have saved the lives of two children in South America. Last month, ScientificAmer ican.com chronicled Giese's remarkable recovery after she had been infected with the deadly virus. In the absence of the vaccine regime or rabies antibodies, the virus kills by interfering with the brain's ability to regulate crucial body functions, including respiration and heart rate. With little hope for Giese's survival, Rodney Willoughby, an infectious disease specialist at the Children' s Hospital of Wisconsin in Milwaukee, induced a coma to protect her brain from viral attack, giving Giese's immune system time to rev up to combat the virus.
Wed Nov 19
If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Antibodies. If you would like to find related tags we recommend Tag Patterns > Antibodies
Off-site Antibodies Research Links
If you still need additional information on Antibodies then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
- A9 > Antibodies
- Alexa > Antibodies
- Anti-Aging Revolution > Antibodies
- DMOZ > Antibodies
- Feeds Filtered > Antibodies
- Google > Antibodies
- News Meme > Antibodies
- Nuah: News > Antibodies
- The Feed Directory > Antibodies
- OBP > Antibodies
- Open Tag Directory > Antibodies
- Podzy > Antibodies
- Yahoo > Antibodies
Cancer Topics
Everything you need to know about Cancer
Cancer
If you know the Cancer Term Name use the links below to quickly jump to your desired focus.
Bookmark Us
The On Topic Network
This website is part of The On Topic Network.
Thank You
Cancer.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.
Best Viewed With
License
This work is licensed under Creative Commons.
